TxCell Receives Approval For Extension Of Phase I/II Clinical Trial In Crohn's Disease

Links shared publicly online about this topic.

  • 284
    total visits

TxCell Receives Approval For Extension Of Phase I/II Clinical Trial In Crohn's Disease

medicalnewstoday.com —

TxCell SA, a biotechnology company developing cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical need, announces today the approval by AFS

View full resource at medicalnewstoday.com

Tags: IBD, Crohn's Disease, Disease and Condition, Clinical Trial, Biotech, disease, Medical

  • Share

Most Recently Shared on May 18, 2011 at 6:05 pm By:

mnt_drugapprov MNT Drug Approvals

TxCell Receives Approval For Extension Of Phase I/II Clinical Trial In Crohn's Disease http://mnt.to/3W3D #regulatory

12 months ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Crohn's / IBD MNT Crohn's / IBD

Advertisement